Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN Jr, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV; NeuroNEXT Clinical Trials Network NN104 Investigators (2019) Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann. Neurol. 85 (1), 125-136.
Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, Fernández JA, Martin G, Kupriyanov S, Mosnier LO, Zlokovic BV, Griffin JH (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131 (11), 1163–1171.
Lyden P, Weymer S, Coffey C, Cudkowicz M, Berg S, O'Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, McNeil E, Waddy S, Pryor K (2016) Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection, Stroke 47 (12), 2979-2985.
Wang Y, Zhao Z, Rege SV, Wang M, Si G, Zhou Y, Wang S, Griffin JH, Goldman SA, Zlokovic BV (2016) 3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice, Nature Medicine 22 (9), 1050-1055. DOI: 10.1038/nm.4154
Lyden P, Levy H, Weymer S, Pryor K, Kramer W, Griffin JH, Davis TP, Zlokovic B (2013) Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Curr Pharm Des. 19 (42), 7479-7485. PMID: 24372304
Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV (2013) Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. Stroke 44 (12), 3529-3536. PMID: 24159062
Mosnier LO, Fernández JA, Davis TP, Zlokovic BV, Griffin JH (2013) Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity. J Thromb Haemost. 11 (11), 2059-2062. PMID: 24034518
Wang Y, Sinha RK, Mosnier LO, Griffin JH, Zlokovic BV (2013) Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol Dis. 51 (2), 104-108. PMID: 23541526
Guo H, Zhao Z, Yang Q, Wang M, Bell R, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV (2013) An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway. J. Neuroscience 33 (14), 6181-6190. Abstract
Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV (2013) Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Res. 1507, 97-104. PMID: 23438513
Williams PD, Zlokovic BV, Griffin JH, Pryor KE, Davis TP (2012) Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Stroke. Curr. Pharm. Des. 18 (27), 4215-4222. PMID: 22632606
Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV (2012) An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tPA for ischemic stroke in rodents. Stroke 43 (9), 2444-2449. PMID: 22811462
Walker, CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV (2010) Activated protein C analog with reduced anti-coagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Research 1347, 125-131. PMID: 20513369
Guo H, Wang Y, Singh I, Liu D, Fernandez JA, Chow N, Zlokovic BV (2009) Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J. Neurochem 109 (1), 116-124. PMCID: PMC2692505
Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV (2009) Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 40 (5), 1864-1869.
Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández J, Chow N, Griffin JH, Zlokovic BV (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur. J. Neurosci. 29, 1119-1130.
Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41, 563-572. PMID: 14980205
Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, Zlokovic BV (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein Nat. Med. 10, 1379-1383. PMID: 15516929
Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9, 338-342. PMID: 12563316
Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799-1805.